Amgen (NASDAQ:?AMGN) and UCB (Euronext Brussels: UCB) today announced that the Japanese Ministry of Health, Labor and Welfare has granted a marketing authorization for EVENITY??(romosozumab) for the treatment of osteoporosis in patients at high risk of fr